Massachusetts Financial Services Co. MA Sells 9,387 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Massachusetts Financial Services Co. MA lessened its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 2.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 314,615 shares of the company’s stock after selling 9,387 shares during the period. Massachusetts Financial Services Co. MA owned 0.52% of Health Catalyst worth $2,224,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Impax Asset Management Group plc increased its position in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after acquiring an additional 195,525 shares during the period. Geode Capital Management LLC grew its stake in Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after purchasing an additional 66,896 shares in the last quarter. State Street Corp increased its holdings in Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares during the period. American Century Companies Inc. raised its position in Health Catalyst by 1.8% during the 4th quarter. American Century Companies Inc. now owns 710,481 shares of the company’s stock valued at $5,023,000 after purchasing an additional 12,682 shares in the last quarter. Finally, Martin & Co. Inc. TN lifted its holdings in shares of Health Catalyst by 80.0% in the 4th quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock worth $3,471,000 after buying an additional 218,293 shares during the period. Institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on HCAT shares. Stifel Nicolaus cut their price target on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Citigroup cut their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Royal Bank of Canada lowered their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $9.27.

Insider Buying and Selling

In related news, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. This trade represents a 7.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now owns 216,250 shares of the company’s stock, valued at $977,450. This trade represents a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,030 shares of company stock worth $263,269 in the last ninety days. 2.50% of the stock is owned by insiders.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $3.82 on Wednesday. Health Catalyst, Inc. has a 12-month low of $3.72 and a 12-month high of $9.24. The business’s fifty day simple moving average is $4.78 and its 200-day simple moving average is $6.61. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $268.21 million, a PE ratio of -2.83 and a beta of 1.43.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.